Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 734,400 shares, a growth of 9.8% from the March 15th total of 669,100 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 3,672.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

OTCMKTS:BIOVF opened at $25.00 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 0.66 and a quick ratio of 0.46. The business has a fifty day simple moving average of $25.59 and a two-hundred day simple moving average of $24.04. Swedish Orphan Biovitrum AB has a 1 year low of $18.35 and a 1 year high of $27.79. The company has a market capitalization of $7.38 billion, a P/E ratio of 34.72 and a beta of 0.49.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) last released its earnings results on Thursday, February 8th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.26). Swedish Orphan Biovitrum AB (publ) had a return on equity of 8.93% and a net margin of 10.95%. The firm had revenue of $643.39 million during the quarter, compared to analysts’ expectations of $668.74 million.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.